Compugen and Mayo Clinic will work together on discovering and validating biomarkers for diagnosing the presence of unstable atherosclerotic plaques in coronary artery disease and cerebrovascular disease.
"Reliably identifying the presence of vulnerable plaques is well recognized as a key unmet diagnostic need,” remarks Anat Cohen-Dayag, Ph.D., vp, diagnostic biomarkers and drug targets. “Therefore, utilizing the unique predictive biology capabilities that have been developed over the past decade at Compugen with relevant data from a world renowned medical center is an extremely exciting opportunity.”
Compugen expects to utilize its discovery engine approach to predict and validate data from biological materials provided by Mayo Clinic, as well as the company’s expression and clinical data. Compugen retains exclusive commercialization rights for products resulting from this collaboration, and Mayo Clinic is entitled to compensation.